key: cord-0793496-wxqfsv35
authors: Dickey, John B.; Albert, Elisabeth; Badr, Mai; Laraja, Kristin M.; Sena, Laureen M.; Gerson, David S.; Saucedo, Jason E.; Qureshi, Waqas; Aurigemma, Gerard P.
title: A Series of Patients with Myocarditis Following SARS-CoV-2 Vaccination with mRNA-1279 and BNT162b2
date: 2021-06-16
journal: JACC Cardiovasc Imaging
DOI: 10.1016/j.jcmg.2021.06.003
sha: ba733297622258b94b202a203050199f9e4462ad
doc_id: 793496
cord_uid: wxqfsv35

nan

Editor's note: Why are we publishing case series raising a possible association between COVID-19 vaccination and myocarditis?

Scientific progress depends upon being open to new ideas and observations. Scientific journals help in this process by providing a platform for such observations, but only after a thoughtful scholarly scrutiny through rigorous peer review. Post-publication debates ensure further critical refinements-some observations stand the test of time while others are discarded. In that spirit, JACC Imaging is publishing 2 small case series of patients where COVID-19 vaccination was "temporally associated with development of myocarditis." Imaging data in such cases is lacking-CMR is now thought to be the closest "non-biopsy" gold standard for diagnosing myocarditis and we felt that documenting CMR findings in such suspected cases would be important.

It is critical to note that:

1. These case series raise the possibility of an association primarily based on the occurrence of myocarditis in close time proximity with COVID-19 vaccination. They do not prove that myocarditis was mediated by COVID-19 vaccination. 2. Myocarditis caused by the usual and more common etiologies is not excluded conclusively. 3. Case series are just observations and meant to spur additional research; we will need to await experience in large populations to understand whether this association is true and what it means. 4. Multiple regulatory agencies, including the CDC, are aware of this association and are evaluating its significance.

We welcome a vigorous, and scholarly scientific debate about the accuracy and significance of these findings.

Wide availability of the three vaccines approved by the U.S. Food and Drug Administration for emergency use against SARS-CoV-2 has led to reports of adverse reactions not seen during clinical trials: We now report a series of patients who developed CMR proven myocarditis shortly after vaccination. 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Post-vaccination myositis and myocarditis in a previously healthy male

Myocarditis secondary to smallpox vaccination